AKTS · Aktis Oncology, Inc.
$18.15
+0.41 (+2.31%)
At close · Oct 9
Return incl. dividend (before tax)
Market Cap
$986.69M
Shares
55.62M
Volume · Oct 9
361.04K
Avg daily vol (3M)
366.04K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$18.15
Open$17.74
Day$17.59–18.21
Available close range$15.19–32.23
Avg vol 30d432K
Short int4.7M · 8.5% float · 7.3d
Short vol54%
DataJan 2026–Oct 2026
Filing10-Q · Aug 13
The closing range uses available history since Jan 9, 2026; less than a full year is stored.
Up next
filed Aug 13, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
—
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
—
Year over year · more shares
Price change (1Y)
—
Trailing year
Short interest
8.5%
Latest settlement · 7.3 days to cover
Equibles Rating
blended score · not investment adviceOverall
Strong Sell
SellHoldBuy
Technical
Sell
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Limited
Quant / Vol
Very High
Market backdrop
VIX 14.8 · calm
Equity put/call 0.56
Technical
price trend
50 / 200-day cross
No cross
Price vs 50-day avg
−21%
below
RSI (14)
29
oversold
MACD trend
Negative
52-week position
17%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−22%
trailing
6-month return
−13%
trailing
Relative strength
−23%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50/200-day averages unavailable
Institutional flow
Accumulating
6 of 113 funds reported for Sep 30 · net +95.3K sh shares · +2 new
Insider flow
Distributing
Net -$196.5K over 90 days · 100% sells
Short interest
Rising
8.48% of float · ▲ +45.0% MoM · 7.3 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
113 holders — 13F breadth
Squeeze score
62
elevated · 0–100
Fundamentals
Not enough data for a confident read.
Quant / Vol
risk profile
Volatility
68%
annualized · 1-yr
Max drawdown
−45%
past year
ATR
6.0%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 50-day avg
−21%
Bearish
RSI (14)
29
Neutral
MACD trend
Negative
Bearish
52-week position
17%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
No cross
50/200-day averages unavailable
Institutional flow
Accumulating
6 of 113 funds reported for Sep 30 · net +95.3K sh shares · +2 new
Insider flow
Distributing
Net -$196.5K over 90 days · 100% sells
Short interest
Rising
8.48% of float · ▲ +45.0% MoM · 7.3 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
113 holders — 13F breadth
Price context
position in its available closing range
Range low $15
Now $18 · 17%
Range high $32
vs 50-day avg -21%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
AKTS
this stock
Aktis Oncology, Inc.
|
$986.69M | — | — | — | 8.5% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$127.55B | +12.5% | +46.2% | 29.3 | 1.8% |
|
MRNA
Moderna, Inc.
|
$89.83B | +663.0% | +4.3% | — | 7.7% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$76.86B | -3.3% | +20.8% | 18.5 | 2.1% |
|
CSLLY
Csl Ltd
|
$61.58B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| AKTS | -2.0% | -22.1% | -12.9% | -6.8% | — |
| SPY | +1.2% | +1.9% | +9.9% | +2.1% | +14.2% |
| vs SPY | -3.2% | -24.0% | -22.7% | -8.9% | — |